Tumour Angiogenesis – The Mechanism and Role in Tumour Progression

Cancer remains one of the leading causes of death worldwide, largely due to its ability to grow uncontrollably and metastasize to distant organs. One of the critical hallmarks that enables this growth and dissemination is tumour angiogenesis—the formation of new blood vessels from pre-existing vasculature in response to signals from the tumour microenvironment. Without angiogenesis, tumours cannot grow beyond a certain size or invade other tissues (Hanahan and Weinberg, 2011). This essay explores the molecular mechanisms that drive tumour angiogenesis, the signaling pathways involved, and how angiogenesis contributes to tumour progression and metastasis.

---

1. Understanding Angiogenesis

Angiogenesis is a normal physiological process involved in growth, development, and wound healing. However, in tumours, this process becomes dysregulated. In healthy tissues, angiogenesis is tightly controlled by a balance between pro-angiogenic and anti-angiogenic factors. tumours disrupt this balance by overproducing pro-angiogenic signals, initiating the “angiogenic switch” (Folkman, 1971).

This switch allows a once-dormant cluster of cancer cells to obtain an adequate supply of oxygen and nutrients, enabling rapid growth and survival in hostile environments. It also facilitates the removal of metabolic waste, creating conditions favorable for further malignancy (Carmeliet and Jain, 2000).

---

2. Mechanism of tumour Angiogenesis

The process of tumour angiogenesis is a complex, multistep phenomenon involving multiple cell types and molecular signals. Key steps include:

A. Hypoxia and the Angiogenic Switch

As tumours grow, their core regions often become hypoxic due to limited oxygen diffusion. Hypoxia is the major driver of the angiogenic switch. In response to hypoxia, tumour cells stabilize hypoxia-inducible factors (HIFs)—especially HIF-1α (Semenza, 2003).

HIF-1α is a transcription factor that activates several genes involved in angiogenesis, most notably the gene encoding vascular endothelial growth factor (VEGF).

B. VEGF Signaling

VEGF is the most potent and well-studied pro-angiogenic factor. It is secreted by tumour cells, stromal cells, and infiltrating immune cells. VEGF binds to its receptors (VEGFR-1, VEGFR-2) on endothelial cells, triggering a cascade of events (Ferrara, 2004):

• Proliferation and migration of endothelial cells

• Degradation of the extracellular matrix (ECM) via matrix metalloproteinases (MMPs)

• Formation of capillary sprouts and tubes

• Recruitment of pericytes and smooth muscle cells for vessel stabilization

Other pro-angiogenic factors include basic fibroblast growth factor (bFGF), angiopoietins, PDGF, and TGF-β (Ribatti and Djonov, 2012).

C. Role of the tumour Microenvironment

tumour angiogenesis is not driven by cancer cells alone. The tumour microenvironment (TME)—including immune cells (e.g., macrophages), fibroblasts, and mesenchymal stem cells—plays a pivotal role (Joyce and Pollard, 2009). These cells produce pro-angiogenic factors and remodel the ECM.

For instance, tumour-associated macrophages (TAMs) secrete VEGF, MMPs, and cytokines that support angiogenesis and cancer cell invasion (Qian and Pollard, 2010).

---

3. Characteristics of tumour Blood Vessels

Blood vessels formed in tumours differ significantly from normal vasculature:

• Structural abnormalities: They are disorganized, tortuous, and leaky.

• Poor perfusion: tumour vessels are inefficient in oxygen delivery, perpetuating hypoxia.

• Heterogeneous distribution: Some regions are highly vascularized while others are avascular (Jain, 2005).

These abnormalities contribute to therapy resistance, metastasis, and an immunosuppressive environment.

---

4. Role of Angiogenesis in tumour Progression

A. Sustained tumour Growth

tumours need a dedicated blood supply to grow beyond 1–2 mm in diameter. Angiogenesis provides the nutrients and oxygen required for sustained proliferation (Bergers and Benjamin, 2003).

B. Metastasis and Invasion

tumour blood vessels serve as conduits for metastasis. Cancer cells intravasate into these vessels, survive in the circulation, and colonize distant tissues (Gupta and Massagué, 2006). Leaky vessels and degraded ECM facilitate this process.

C. Resistance to Therapy

Poorly structured vasculature impairs drug delivery and reduces oxygenation, which diminishes the efficacy of chemotherapy and radiotherapy (Dewhirst, Cao and Moeller, 2008). Additionally, hypoxia drives the selection of more aggressive, treatment-resistant cancer clones.

---

5. Therapeutic Targeting of Tumour Angiogenesis

Given its importance in cancer biology, angiogenesis is a major therapeutic target.

A. Anti-VEGF Therapies

Bevacizumab, a monoclonal antibody against VEGF-A, was one of the first FDA-approved anti-angiogenic drugs (Hurwitz et al., 2004). Other agents like sunitinib and sorafenib block VEGFR signaling and have shown benefit in several cancers, including renal cell carcinoma and glioblastoma (Escudier et al., 2007).

B. Challenges and Resistance

Despite clinical success, anti-angiogenic therapies face limitations:

• Adaptive resistance: tumours upregulate alternative pathways (e.g., FGF, PDGF).

• Transient benefit: Responses are often temporary.

• Side effects: Including hypertension and impaired wound healing (Bergers and Hanahan, 2008).

Newer approaches focus on vascular normalization, which aims to improve perfusion and drug delivery by making tumour vessels more “normal” in structure and function (Jain, 2014).

---

6. Future Perspectives

Ongoing research focuses on:

• Biomarkers to identify responders to anti-angiogenic therapy

• Combination strategies (e.g., with immunotherapy or chemotherapy)

• Targeting the TME to inhibit supportive stromal and immune cells

• Personalized approaches based on angiogenic signatures (Batchelor et al., 2013)

Understanding the interplay between angiogenesis and immune suppression is also providing new insights for cancer immunotherapy.

---

Conclusion

tumour angiogenesis is a fundamental enabler of cancer progression. Driven by hypoxia and pro-angiogenic signaling—especially via the VEGF pathway—angiogenesis sustains tumour growth, facilitates metastasis, and contributes to therapy resistance. Although anti-angiogenic therapy has shown promise, resistance and limited efficacy remain challenges. Future strategies that integrate angiogenesis inhibition with other modalities, guided by biomarker-driven personalization, hold potential to enhance outcomes in cancer treatment.

---

References

Batchelor, T.T., Mulholland, P., Neyns, B., Nabors, L.B., Campone, M., Wick, A., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Rosenthal, M., De Groot, J.F., Balana, C., Reardon, D.A., Galanis, E., O’Neill, A., Buxton, R., Akimov, M., Pineda, E., Phuphanich, S. and Chinot, O.L., 2013. Phase III randomized trial comparing the efficacy of enzastaurin versus lomustine in the treatment of recurrent glioblastoma. Journal of Clinical Oncology, 31(25), pp.3212–3218.

Bergers, G. and Benjamin, L.E., 2003. Tumorigenesis and the angiogenic switch. Nature Reviews Cancer, 3(6), pp.401–410.

Bergers, G. and Hanahan, D., 2008. Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 8(8), pp.592–603.

Carmeliet, P. and Jain, R.K., 2000. Angiogenesis in cancer and other diseases. Nature, 407(6801), pp.249–257.

Dewhirst, M.W., Cao, Y. and Moeller, B., 2008. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Reviews Cancer, 8(6), pp.425–437.

Escudier, B., Eisen, T., Stadler, W.M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A.A., Rolland, F., Demkow, T., Hutson, T.E., Gore, M., Freeman, S., Schwartz, B., Shan, M., Simantov, R. and Bukowski, R.M., 2007. Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine, 356(2), pp.125–134.

Ferrara, N., 2004. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews, 25(4), pp.581–611.

Folkman, J., 1971. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285(21), pp.1182–1186.

Gupta, G.P. and Massagué, J., 2006. Cancer metastasis: building a framework. Cell, 127(4), pp.679–695.

Hanahan, D. and Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. Cell, 144(5), pp.646–674.

Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R. and Kabbinavar, F., 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350(23), pp.2335–2342.

Jain, R.K., 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307(5706), pp.58–62.

Jain, R.K., 2014. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell, 26(5), pp.605–622.

Joyce, J.A. and Pollard, J.W., 2009. Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9(4), pp.239–252.

Qian, B. and Pollard, J.W., 2010. Macrophage diversity enhances tumor progression and metastasis. Cell, 141(1), pp.39–51.

Ribatti, D. and Djonov, V., 2012. Intussusceptive microvascular growth in tumors. Cancer Letters, 316(2), pp.126–131.

Semenza, G.L., 2003. Targeting HIF-1 for cancer therapy. Nature Reviews Cancer, 3(10), pp.721–732.